US Stem Cell (OTCMKTS:USRM) and AIkido Pharma (NASDAQ:AIKI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.
Risk and Volatility
US Stem Cell has a beta of 3.49, suggesting that its share price is 249% more volatile than the S&P 500. Comparatively, AIkido Pharma has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Valuation and Earnings
This table compares US Stem Cell and AIkido Pharma’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|US Stem Cell||$6.70 million||0.37||-$2.16 million||N/A||N/A|
|AIkido Pharma||$10,000.00||3,113.82||-$4.18 million||N/A||N/A|
US Stem Cell has higher revenue and earnings than AIkido Pharma.
This table compares US Stem Cell and AIkido Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|US Stem Cell||-81.39%||N/A||-313.05%|
Insider and Institutional Ownership
0.9% of AIkido Pharma shares are held by institutional investors. 16.7% of US Stem Cell shares are held by company insiders. Comparatively, 4.2% of AIkido Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for US Stem Cell and AIkido Pharma, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|US Stem Cell||0||0||0||0||N/A|
US Stem Cell beats AIkido Pharma on 5 of the 9 factors compared between the two stocks.
US Stem Cell Company Profile
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.
AIkido Pharma Company Profile
AIkido Pharma Inc., a biotechnology development company, focuses on developing small-molecule anti-cancer therapeutics. The company engages in the development of therapeutic drugs for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Its portfolio includes KPC-34 for the treatment of AML and ALL; and DHA-dFdC drug for the treatment of pancreatic cancer. AIkido Pharma Inc. has an artificial intelligence and machine learning research agreement with Cogia Biotech LTD. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2020. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.
Receive News & Ratings for US Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for US Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.